{
    "id": 28145,
    "fullName": "MSI low",
    "impact": "",
    "proteinEffect": "",
    "geneVariantDescriptions": [
        {
            "description": "MSI low indicates a low level of microsatellite instability.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 999999992,
        "geneSymbol": "MSI",
        "terms": [
            "MSI",
            "Microsatellite Instability"
        ]
    },
    "variant": "low",
    "createDate": "05/03/2018",
    "updateDate": "05/03/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18986,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (Study 111/KEYNOTE-146) that supported FDA approval, Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination treatment resulted in an objective response rate of 35.6% (16/45) in patients with endometrial carcinoma that was not MSI-H or dMMR (PMID: 30922731; NCT02501096).",
            "molecularProfile": {
                "id": 29715,
                "profileName": "MSI low"
            },
            "therapy": {
                "id": 4782,
                "therapyName": "Lenvatinib + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 2871,
                "name": "endometrial carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16267,
                    "pubMedId": 30922731,
                    "title": "Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30922731"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15032,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with gastroesophageal junction adenocarcinoma with Mdm2 amplification, low tumor mutational burden, and MSI stable, had hyperprogression after treatment with Opdivo (nivolumab) (PMID: 30148248).",
            "molecularProfile": {
                "id": 30606,
                "profileName": "MDM2 amp MSI low TMB low"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12407,
                    "pubMedId": 30148248,
                    "title": "Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30148248"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29715,
            "profileName": "MSI low",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30606,
            "profileName": "MDM2 amp MSI low TMB low",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}